Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Saxenda · Victoza
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GLP-1 peptide analogue
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
GLP-1 receptor agonism affecting appetite and glucose physiology.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Reported weight management
GLP-1 analogue with product/indication-specific dosing; not every vial is Saxenda/Victoza.
Human evidence
SCALE randomized trial supports weight management in its population; diabetes and obesity products have different indications.
Preclinical evidence
Mechanistic evidence does not justify adding other GLP-1 drugs.
Critical reading and limitations
SCALE enrolled 3,731 adults and showed greater weight loss; daily dosing cannot be converted to weekly dosing.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
3 mg · Target maintenance amount; not a starting amount
- Frequency
- Daily
- Duration
- 56 weeks
- Route
- Subcutaneous
- Context
- SCALE: 3,731 adults, weight management; study product/escalation.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID26132939 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
EU: Saxenda authorized for weight management in defined age/BMI/weight groups. Separate US label review pending.
Adverse effects and unknowns
GI adverse effects are common. Full contraindication and interaction extraction must use the exact current product label; do not copy another GLP-1 label.
GI events and label precautions; do not attribute monotherapy safety to mixtures.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Liraglutide · 514 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07677865 · GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationRegistry status: WithdrawnLast update posted: October 16, 2026Query verification: October 16, 2026
NCT06726577 · TP04HN106 in the Treatment of Patients With Amyotrophic Lateral SclerosisRegistry status: RecruitingLast update posted: October 2, 2026Query verification: October 16, 2026
NCT07225829 · A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisRegistry status: Active, not recruitingLast update posted: September 21, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-SAX
October 16, 2026
- PMID26132939
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group.
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026